Navigation Links
Notice of Time Change for Alexion's Presentation at the Bank of America 2008 Health Care Conference
Date:5/9/2008

CHESHIRE, Conn., May 9 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the time of Alexion's presentation at the Bank of America 2008 Health Care Conference in Las Vegas has been changed to 4:00 p.m., local time (7:00 p.m., eastern) on Tuesday, May 13, 2008. Vikas Sinha, Senior Vice President and Chief Financial Officer, is scheduled to present.

An audio webcast of Mr. Sinha's remarks will be available live. You can access the webcast at: http://www.alexionpharm.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

[ALXN-G]


'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast
2. Notice of conference call and webcast
3. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
4. Tapestry Receives Nasdaq Delisting Notice
5. Genmab A/S - Notice to Convene Annual General Meeting
6. EntreMed Receives Nasdaq Deficiency Notice
7. Vermillion Receives NASDAQ Notice of Non-Compliance
8. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
9. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
10. Genta Receives Notice of Non-Compliance With NASDAQ Rule
11. HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., SANTACRUZ,Calif.,Nov.24/PRNewswire/--Twomorep...enation,sleadingonlinejobboardandcareerssiteforlif...iaUniversityarenowmembersofthejobboard,joining28ot...jobboard, www.biocareercenter.com ,isonlyforpost-g...ifesciencecareersitesontheInternet,BioCareerCenter...
(Date:11/24/2009)... Health care employment gr...s the only one to show consistent growth during th...ospitals remain in trouble, and health systems are...ersonnel, instead of just administrators. , ...alth care employment continued growing in October ...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBio...ration(SFDA)hasapprovedthe,investigationalnewdruga...ninnovativeinsulinformulationtotreatdiabetes.ThisI...inicalstudy. , Diabetesisadisordercharacteris...ationsofdiabetesoftenresultinseveremicro-and,macro...
(Date:11/24/2009)..., TSXVENTURE:HTL , TORONTO,Nov.24/PRNewswi...lyCalottoCapitalInc.,aleadingproviderofadvancedlas...rtilityclinicmarkets,todayreportedoperationalandfi...009. , ,Q32009Highlights,-Revenuewas$1.46million...nwas66.3percentcomparedwith66.1percentinQ3,2008,-N...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7
...any health plans are moving to in-source Disease M... costs and improve member outcomes , , , ,...nagement Solution(IHMS) platform fully integrates ... , , , , , , Blue Cross Blue Shi...to improve care and manage members, healthcare mor...
...., Feb. 2 MannKind Corporation (Nasdaq: MNKD ),...izing treatments for diabetes and cancer, announce...otechnology Industry Organization BIO CEO & In...:15 PM (EST) at the Hilton Waldorf Astoria in New ... Company will host a breakfast meeting for invited...
...ruary 2 Axentis Pharma AG is to present its,recen...apeutic formulation,for treating chronic lung dise...rum in Zurich, Switzerland. This invited talk come...present its recent achievements at the Biotech,Sho...any,s ongoing success,story is a recent capital in...
Other Biology Technology:Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 2Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 3Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 4MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 3
(Date:11/24/2009)...ntarctica has long held secrets of the earth,s his... there has been very little information on the env...ce for millions of years. Now, a team of researche...n funded to the tune of $10 million dollars by the...e bottom of things literally. These scientists wi...
(Date:11/23/2009)... The community-associated strain of the deadly su... to most common antibioticsposes a far greater hea... way into hospitals, according to a study in the D..., The new threat is easily picked up in fitness ...increased the overall burden of MRSA within hospit...
(Date:11/23/2009)...Current research suggests that a common oral bacte...ed report by Nichols et al, "Unique Lipids from a ...R2 Ligands Capable of Enhancing Autoimmunity," app...ournal of Pathology . , Multiple sclerosis (MS),...in and spinal cord, affects nearly 1 in 700 people...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Authentidate Holding Corp to Report Fourth Quarter and Fiscal Year End 2009 Results on Thursday September 24 2009 56739 1Authentidate Holding Corp to Report Fourth Quarter and Fiscal Year End 2009 Results on Thursday September 24 2009 56739 2Abaxis Inc to Present at the ThinkEquity Sixth Annual Growth Conference 56737 1PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 1PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 2PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 3PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 4PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 5PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 6
...e and then presented with a chemoattractant signal... a polarized morphology and aggregate to form a mi...pmental program that culminates in the formation o...w this streaming response is coordinated at a sing... Journal of Cell Biology ( www.jcb.org ). , Bes...
... chest wall deformity known as pectus excavatum co...exercise, according to a study published December ...ed at 11 North American hospitals, involved teleph...he ages of 8 and 21 who had pectus excavatum surge...he results were dramatic. Patients reported greatl...
...ant that has a potent effect on gene activity, cou...n the December issue of BioScience . The chemical...d and textile preservative, and as a pesticide on ...ns. , Tributyltin affects sensitive receptors in ...at very low concentrationsa thousand times lower t...
Other Biology News:Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3Persistent pollutant may promote obesity 2
Newborn Calf Serum from Lifeblood Medical, Inc.
Normal Calf Serum from Equitech-Bio
Custom DNA Primers from Invitrogen
Direct ELISA Assay Diluent from BioFX Laboratories, Inc.
Biology Products: